[
    {
        "molecule_name": "Antibodies of the present invention",
        "protein_target_name": "CLDN6",
        "binding_metric": "KD",
        "value": "1-100",
        "unit": "nM",
        "raw_mentions": "Antibodies of the present invention preferably dissociate from CLDN6 with a dissociation equilibrium constant (KD) of approximately 1-100 nM or less.\nIn preferred embodiments, antibodies of the present invention can be characterized by one or more of the following properties: b) a binding affinity to CLDN6 of about 100 nM or less, preferably, about 5-10 nM or less and, more preferably, about 1-3 nM or less,"
    },
    {
        "molecule_name": "Antibodies of the present invention",
        "protein_target_name": "CLDN6",
        "binding_metric": "binding affinity",
        "value": "100",
        "unit": "nM",
        "raw_mentions": "Antibodies of the present invention preferably dissociate from CLDN6 with a dissociation equilibrium constant (KD) of approximately 1-100 nM or less.\nIn preferred embodiments, antibodies of the present invention can be characterized by one or more of the following properties: b) a binding affinity to CLDN6 of about 100 nM or less, preferably, about 5-10 nM or less and, more preferably, about 1-3 nM or less,"
    },
    {
        "molecule_name": "Antibodies of the present invention",
        "protein_target_name": "CLDN6",
        "binding_metric": "binding affinity",
        "value": "5-10",
        "unit": "nM",
        "raw_mentions": "Antibodies of the present invention preferably dissociate from CLDN6 with a dissociation equilibrium constant (KD) of approximately 1-100 nM or less.\nIn preferred embodiments, antibodies of the present invention can be characterized by one or more of the following properties: b) a binding affinity to CLDN6 of about 100 nM or less, preferably, about 5-10 nM or less and, more preferably, about 1-3 nM or less,"
    },
    {
        "molecule_name": "Antibodies of the present invention",
        "protein_target_name": "CLDN6",
        "binding_metric": "binding affinity",
        "value": "1-3",
        "unit": "nM",
        "raw_mentions": "Antibodies of the present invention preferably dissociate from CLDN6 with a dissociation equilibrium constant (KD) of approximately 1-100 nM or less.\nIn preferred embodiments, antibodies of the present invention can be characterized by one or more of the following properties: b) a binding affinity to CLDN6 of about 100 nM or less, preferably, about 5-10 nM or less and, more preferably, about 1-3 nM or less,"
    },
    {
        "molecule_name": "Antibodies of the present invention",
        "protein_target_name": "CLDN6",
        "binding_metric": "EC50",
        "value": "6500",
        "unit": "ng/ml",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nAntibodies of the present invention preferably have EC50 values for binding to CLDN6 of 6500 ng/ml or lower, 3000 ng/ml or lower, 2500 ng/ml or lower, 2000 ng/ml or lower, 1500 ng/ml or lower, 1000 ng/ml or lower, 500 ng/ml or lower, 400 ng/ml or lower, 300 ng/ml or lower, 200 ng/ml or lower, or 100 ng/ml or lower.\nPreferably, the term \"significant affinity\" refers to the binding to a predetermined target with a dissociation constant (K<sub>D</sub>) of 10<sup>-5</sup> M or lower, 10<sup>-6</sup> M or lower, 10<sup>-7</sup> M or lower, 10<sup>-8</sup> M or lower, 10<sup>-9</sup> M or lower, 10<sup>-10</sup> M or lower, 10<sup>-11</sup> M or lower, or 10<sup>-12</sup> M or lower."
    },
    {
        "molecule_name": "Antibodies of the present invention",
        "protein_target_name": "CLDN6",
        "binding_metric": "EC50",
        "value": "3000",
        "unit": "ng/ml",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nAntibodies of the present invention preferably have EC50 values for binding to CLDN6 of 6500 ng/ml or lower, 3000 ng/ml or lower, 2500 ng/ml or lower, 2000 ng/ml or lower, 1500 ng/ml or lower, 1000 ng/ml or lower, 500 ng/ml or lower, 400 ng/ml or lower, 300 ng/ml or lower, 200 ng/ml or lower, or 100 ng/ml or lower.\nPreferably, the term \"significant affinity\" refers to the binding to a predetermined target with a dissociation constant (K<sub>D</sub>) of 10<sup>-5</sup> M or lower, 10<sup>-6</sup> M or lower, 10<sup>-7</sup> M or lower, 10<sup>-8</sup> M or lower, 10<sup>-9</sup> M or lower, 10<sup>-10</sup> M or lower, 10<sup>-11</sup> M or lower, or 10<sup>-12</sup> M or lower."
    },
    {
        "molecule_name": "Antibodies of the present invention",
        "protein_target_name": "CLDN6",
        "binding_metric": "EC50",
        "value": "2500",
        "unit": "ng/ml",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nAntibodies of the present invention preferably have EC50 values for binding to CLDN6 of 6500 ng/ml or lower, 3000 ng/ml or lower, 2500 ng/ml or lower, 2000 ng/ml or lower, 1500 ng/ml or lower, 1000 ng/ml or lower, 500 ng/ml or lower, 400 ng/ml or lower, 300 ng/ml or lower, 200 ng/ml or lower, or 100 ng/ml or lower.\nPreferably, the term \"significant affinity\" refers to the binding to a predetermined target with a dissociation constant (K<sub>D</sub>) of 10<sup>-5</sup> M or lower, 10<sup>-6</sup> M or lower, 10<sup>-7</sup> M or lower, 10<sup>-8</sup> M or lower, 10<sup>-9</sup> M or lower, 10<sup>-10</sup> M or lower, 10<sup>-11</sup> M or lower, or 10<sup>-12</sup> M or lower."
    },
    {
        "molecule_name": "Antibodies of the present invention",
        "protein_target_name": "CLDN6",
        "binding_metric": "EC50",
        "value": "2000",
        "unit": "ng/ml",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nAntibodies of the present invention preferably have EC50 values for binding to CLDN6 of 6500 ng/ml or lower, 3000 ng/ml or lower, 2500 ng/ml or lower, 2000 ng/ml or lower, 1500 ng/ml or lower, 1000 ng/ml or lower, 500 ng/ml or lower, 400 ng/ml or lower, 300 ng/ml or lower, 200 ng/ml or lower, or 100 ng/ml or lower.\nPreferably, the term \"significant affinity\" refers to the binding to a predetermined target with a dissociation constant (K<sub>D</sub>) of 10<sup>-5</sup> M or lower, 10<sup>-6</sup> M or lower, 10<sup>-7</sup> M or lower, 10<sup>-8</sup> M or lower, 10<sup>-9</sup> M or lower, 10<sup>-10</sup> M or lower, 10<sup>-11</sup> M or lower, or 10<sup>-12</sup> M or lower."
    },
    {
        "molecule_name": "Antibodies of the present invention",
        "protein_target_name": "CLDN6",
        "binding_metric": "EC50",
        "value": "1500",
        "unit": "ng/ml",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nAntibodies of the present invention preferably have EC50 values for binding to CLDN6 of 6500 ng/ml or lower, 3000 ng/ml or lower, 2500 ng/ml or lower, 2000 ng/ml or lower, 1500 ng/ml or lower, 1000 ng/ml or lower, 500 ng/ml or lower, 400 ng/ml or lower, 300 ng/ml or lower, 200 ng/ml or lower, or 100 ng/ml or lower.\nPreferably, the term \"significant affinity\" refers to the binding to a predetermined target with a dissociation constant (K<sub>D</sub>) of 10<sup>-5</sup> M or lower, 10<sup>-6</sup> M or lower, 10<sup>-7</sup> M or lower, 10<sup>-8</sup> M or lower, 10<sup>-9</sup> M or lower, 10<sup>-10</sup> M or lower, 10<sup>-11</sup> M or lower, or 10<sup>-12</sup> M or lower."
    },
    {
        "molecule_name": "Antibodies of the present invention",
        "protein_target_name": "CLDN6",
        "binding_metric": "EC50",
        "value": "1000",
        "unit": "ng/ml",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nAntibodies of the present invention preferably have EC50 values for binding to CLDN6 of 6500 ng/ml or lower, 3000 ng/ml or lower, 2500 ng/ml or lower, 2000 ng/ml or lower, 1500 ng/ml or lower, 1000 ng/ml or lower, 500 ng/ml or lower, 400 ng/ml or lower, 300 ng/ml or lower, 200 ng/ml or lower, or 100 ng/ml or lower.\nPreferably, the term \"significant affinity\" refers to the binding to a predetermined target with a dissociation constant (K<sub>D</sub>) of 10<sup>-5</sup> M or lower, 10<sup>-6</sup> M or lower, 10<sup>-7</sup> M or lower, 10<sup>-8</sup> M or lower, 10<sup>-9</sup> M or lower, 10<sup>-10</sup> M or lower, 10<sup>-11</sup> M or lower, or 10<sup>-12</sup> M or lower."
    },
    {
        "molecule_name": "Antibodies of the present invention",
        "protein_target_name": "CLDN6",
        "binding_metric": "EC50",
        "value": "500",
        "unit": "ng/ml",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nAntibodies of the present invention preferably have EC50 values for binding to CLDN6 of 6500 ng/ml or lower, 3000 ng/ml or lower, 2500 ng/ml or lower, 2000 ng/ml or lower, 1500 ng/ml or lower, 1000 ng/ml or lower, 500 ng/ml or lower, 400 ng/ml or lower, 300 ng/ml or lower, 200 ng/ml or lower, or 100 ng/ml or lower.\nPreferably, the term \"significant affinity\" refers to the binding to a predetermined target with a dissociation constant (K<sub>D</sub>) of 10<sup>-5</sup> M or lower, 10<sup>-6</sup> M or lower, 10<sup>-7</sup> M or lower, 10<sup>-8</sup> M or lower, 10<sup>-9</sup> M or lower, 10<sup>-10</sup> M or lower, 10<sup>-11</sup> M or lower, or 10<sup>-12</sup> M or lower."
    },
    {
        "molecule_name": "Antibodies of the present invention",
        "protein_target_name": "CLDN6",
        "binding_metric": "EC50",
        "value": "400",
        "unit": "ng/ml",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nAntibodies of the present invention preferably have EC50 values for binding to CLDN6 of 6500 ng/ml or lower, 3000 ng/ml or lower, 2500 ng/ml or lower, 2000 ng/ml or lower, 1500 ng/ml or lower, 1000 ng/ml or lower, 500 ng/ml or lower, 400 ng/ml or lower, 300 ng/ml or lower, 200 ng/ml or lower, or 100 ng/ml or lower.\nPreferably, the term \"significant affinity\" refers to the binding to a predetermined target with a dissociation constant (K<sub>D</sub>) of 10<sup>-5</sup> M or lower, 10<sup>-6</sup> M or lower, 10<sup>-7</sup> M or lower, 10<sup>-8</sup> M or lower, 10<sup>-9</sup> M or lower, 10<sup>-10</sup> M or lower, 10<sup>-11</sup> M or lower, or 10<sup>-12</sup> M or lower."
    },
    {
        "molecule_name": "Antibodies of the present invention",
        "protein_target_name": "CLDN6",
        "binding_metric": "EC50",
        "value": "300",
        "unit": "ng/ml",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nAntibodies of the present invention preferably have EC50 values for binding to CLDN6 of 6500 ng/ml or lower, 3000 ng/ml or lower, 2500 ng/ml or lower, 2000 ng/ml or lower, 1500 ng/ml or lower, 1000 ng/ml or lower, 500 ng/ml or lower, 400 ng/ml or lower, 300 ng/ml or lower, 200 ng/ml or lower, or 100 ng/ml or lower.\nPreferably, the term \"significant affinity\" refers to the binding to a predetermined target with a dissociation constant (K<sub>D</sub>) of 10<sup>-5</sup> M or lower, 10<sup>-6</sup> M or lower, 10<sup>-7</sup> M or lower, 10<sup>-8</sup> M or lower, 10<sup>-9</sup> M or lower, 10<sup>-10</sup> M or lower, 10<sup>-11</sup> M or lower, or 10<sup>-12</sup> M or lower."
    },
    {
        "molecule_name": "Antibodies of the present invention",
        "protein_target_name": "CLDN6",
        "binding_metric": "EC50",
        "value": "200",
        "unit": "ng/ml",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nAntibodies of the present invention preferably have EC50 values for binding to CLDN6 of 6500 ng/ml or lower, 3000 ng/ml or lower, 2500 ng/ml or lower, 2000 ng/ml or lower, 1500 ng/ml or lower, 1000 ng/ml or lower, 500 ng/ml or lower, 400 ng/ml or lower, 300 ng/ml or lower, 200 ng/ml or lower, or 100 ng/ml or lower.\nPreferably, the term \"significant affinity\" refers to the binding to a predetermined target with a dissociation constant (K<sub>D</sub>) of 10<sup>-5</sup> M or lower, 10<sup>-6</sup> M or lower, 10<sup>-7</sup> M or lower, 10<sup>-8</sup> M or lower, 10<sup>-9</sup> M or lower, 10<sup>-10</sup> M or lower, 10<sup>-11</sup> M or lower, or 10<sup>-12</sup> M or lower."
    },
    {
        "molecule_name": "Antibodies of the present invention",
        "protein_target_name": "CLDN6",
        "binding_metric": "EC50",
        "value": "100",
        "unit": "ng/ml",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nAntibodies of the present invention preferably have EC50 values for binding to CLDN6 of 6500 ng/ml or lower, 3000 ng/ml or lower, 2500 ng/ml or lower, 2000 ng/ml or lower, 1500 ng/ml or lower, 1000 ng/ml or lower, 500 ng/ml or lower, 400 ng/ml or lower, 300 ng/ml or lower, 200 ng/ml or lower, or 100 ng/ml or lower.\nPreferably, the term \"significant affinity\" refers to the binding to a predetermined target with a dissociation constant (K<sub>D</sub>) of 10<sup>-5</sup> M or lower, 10<sup>-6</sup> M or lower, 10<sup>-7</sup> M or lower, 10<sup>-8</sup> M or lower, 10<sup>-9</sup> M or lower, 10<sup>-10</sup> M or lower, 10<sup>-11</sup> M or lower, or 10<sup>-12</sup> M or lower."
    },
    {
        "molecule_name": "chimAB 64A",
        "protein_target_name": "CLDN6",
        "binding_metric": "EC50",
        "value": "450-600",
        "unit": "ng/ml",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nRegarding binding to human CLDN6 stably expressed on the surface of HEK293 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibit very low EC50 values (EC50 450-600 ng/ml) and saturation of binding was achieved at low concentrations.\nChimAB 67A and 61D showed low (EC50 1000 ng/ml) and medium (EC50 2300 ng/ml) EC50 values, respectively (Fig. 12).\nRegarding binding to CLDN6 endogenously expressed in NEC8 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibited very low EC50 values (EC50 600-650 ng/ml) and saturation of binding was achieved at low concentrations, whereas chimAB 61D and 67A showed medium (EC50 1700 ng/ml) and high (EC50 6100 ng/ml) EC50 values, respectively (Fig. 13).\nRegarding binding to CLDN6 endogenously expressed in OV90 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibited very low EC50 values (EC50 550-600 ng/ml) and saturation of binding was achieved at low concentrations.\nChimAB 61D and 67A showed medium EC50 values (EC50 1500 ng/ml and EC50 2300 ng/ml, respectively) (Fig. 14)."
    },
    {
        "molecule_name": "chimAB 89A",
        "protein_target_name": "CLDN6",
        "binding_metric": "EC50",
        "value": "450-600",
        "unit": "ng/ml",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nRegarding binding to human CLDN6 stably expressed on the surface of HEK293 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibit very low EC50 values (EC50 450-600 ng/ml) and saturation of binding was achieved at low concentrations.\nChimAB 67A and 61D showed low (EC50 1000 ng/ml) and medium (EC50 2300 ng/ml) EC50 values, respectively (Fig. 12).\nRegarding binding to CLDN6 endogenously expressed in NEC8 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibited very low EC50 values (EC50 600-650 ng/ml) and saturation of binding was achieved at low concentrations, whereas chimAB 61D and 67A showed medium (EC50 1700 ng/ml) and high (EC50 6100 ng/ml) EC50 values, respectively (Fig. 13).\nRegarding binding to CLDN6 endogenously expressed in OV90 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibited very low EC50 values (EC50 550-600 ng/ml) and saturation of binding was achieved at low concentrations.\nChimAB 61D and 67A showed medium EC50 values (EC50 1500 ng/ml and EC50 2300 ng/ml, respectively) (Fig. 14)."
    },
    {
        "molecule_name": "chimAB 67A",
        "protein_target_name": "CLDN6",
        "binding_metric": "EC50",
        "value": "1000",
        "unit": "ng/ml",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nRegarding binding to human CLDN6 stably expressed on the surface of HEK293 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibit very low EC50 values (EC50 450-600 ng/ml) and saturation of binding was achieved at low concentrations.\nChimAB 67A and 61D showed low (EC50 1000 ng/ml) and medium (EC50 2300 ng/ml) EC50 values, respectively (Fig. 12).\nRegarding binding to CLDN6 endogenously expressed in NEC8 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibited very low EC50 values (EC50 600-650 ng/ml) and saturation of binding was achieved at low concentrations, whereas chimAB 61D and 67A showed medium (EC50 1700 ng/ml) and high (EC50 6100 ng/ml) EC50 values, respectively (Fig. 13).\nRegarding binding to CLDN6 endogenously expressed in OV90 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibited very low EC50 values (EC50 550-600 ng/ml) and saturation of binding was achieved at low concentrations.\nChimAB 61D and 67A showed medium EC50 values (EC50 1500 ng/ml and EC50 2300 ng/ml, respectively) (Fig. 14)."
    },
    {
        "molecule_name": "chimAB 61D",
        "protein_target_name": "CLDN6",
        "binding_metric": "EC50",
        "value": "2300",
        "unit": "ng/ml",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nRegarding binding to human CLDN6 stably expressed on the surface of HEK293 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibit very low EC50 values (EC50 450-600 ng/ml) and saturation of binding was achieved at low concentrations.\nChimAB 67A and 61D showed low (EC50 1000 ng/ml) and medium (EC50 2300 ng/ml) EC50 values, respectively (Fig. 12).\nRegarding binding to CLDN6 endogenously expressed in NEC8 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibited very low EC50 values (EC50 600-650 ng/ml) and saturation of binding was achieved at low concentrations, whereas chimAB 61D and 67A showed medium (EC50 1700 ng/ml) and high (EC50 6100 ng/ml) EC50 values, respectively (Fig. 13).\nRegarding binding to CLDN6 endogenously expressed in OV90 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibited very low EC50 values (EC50 550-600 ng/ml) and saturation of binding was achieved at low concentrations.\nChimAB 61D and 67A showed medium EC50 values (EC50 1500 ng/ml and EC50 2300 ng/ml, respectively) (Fig. 14)."
    },
    {
        "molecule_name": "chimAB 64A",
        "protein_target_name": "CLDN6",
        "binding_metric": "EC50",
        "value": "600-650",
        "unit": "ng/ml",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nRegarding binding to human CLDN6 stably expressed on the surface of HEK293 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibit very low EC50 values (EC50 450-600 ng/ml) and saturation of binding was achieved at low concentrations.\nChimAB 67A and 61D showed low (EC50 1000 ng/ml) and medium (EC50 2300 ng/ml) EC50 values, respectively (Fig. 12).\nRegarding binding to CLDN6 endogenously expressed in NEC8 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibited very low EC50 values (EC50 600-650 ng/ml) and saturation of binding was achieved at low concentrations, whereas chimAB 61D and 67A showed medium (EC50 1700 ng/ml) and high (EC50 6100 ng/ml) EC50 values, respectively (Fig. 13).\nRegarding binding to CLDN6 endogenously expressed in OV90 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibited very low EC50 values (EC50 550-600 ng/ml) and saturation of binding was achieved at low concentrations.\nChimAB 61D and 67A showed medium EC50 values (EC50 1500 ng/ml and EC50 2300 ng/ml, respectively) (Fig. 14)."
    },
    {
        "molecule_name": "chimAB 89A",
        "protein_target_name": "CLDN6",
        "binding_metric": "EC50",
        "value": "600-650",
        "unit": "ng/ml",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nRegarding binding to human CLDN6 stably expressed on the surface of HEK293 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibit very low EC50 values (EC50 450-600 ng/ml) and saturation of binding was achieved at low concentrations.\nChimAB 67A and 61D showed low (EC50 1000 ng/ml) and medium (EC50 2300 ng/ml) EC50 values, respectively (Fig. 12).\nRegarding binding to CLDN6 endogenously expressed in NEC8 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibited very low EC50 values (EC50 600-650 ng/ml) and saturation of binding was achieved at low concentrations, whereas chimAB 61D and 67A showed medium (EC50 1700 ng/ml) and high (EC50 6100 ng/ml) EC50 values, respectively (Fig. 13).\nRegarding binding to CLDN6 endogenously expressed in OV90 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibited very low EC50 values (EC50 550-600 ng/ml) and saturation of binding was achieved at low concentrations.\nChimAB 61D and 67A showed medium EC50 values (EC50 1500 ng/ml and EC50 2300 ng/ml, respectively) (Fig. 14)."
    },
    {
        "molecule_name": "chimAB 61D",
        "protein_target_name": "CLDN6",
        "binding_metric": "EC50",
        "value": "1700",
        "unit": "ng/ml",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nRegarding binding to human CLDN6 stably expressed on the surface of HEK293 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibit very low EC50 values (EC50 450-600 ng/ml) and saturation of binding was achieved at low concentrations.\nChimAB 67A and 61D showed low (EC50 1000 ng/ml) and medium (EC50 2300 ng/ml) EC50 values, respectively (Fig. 12).\nRegarding binding to CLDN6 endogenously expressed in NEC8 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibited very low EC50 values (EC50 600-650 ng/ml) and saturation of binding was achieved at low concentrations, whereas chimAB 61D and 67A showed medium (EC50 1700 ng/ml) and high (EC50 6100 ng/ml) EC50 values, respectively (Fig. 13).\nRegarding binding to CLDN6 endogenously expressed in OV90 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibited very low EC50 values (EC50 550-600 ng/ml) and saturation of binding was achieved at low concentrations.\nChimAB 61D and 67A showed medium EC50 values (EC50 1500 ng/ml and EC50 2300 ng/ml, respectively) (Fig. 14)."
    },
    {
        "molecule_name": "chimAB 67A",
        "protein_target_name": "CLDN6",
        "binding_metric": "EC50",
        "value": "6100",
        "unit": "ng/ml",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nRegarding binding to human CLDN6 stably expressed on the surface of HEK293 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibit very low EC50 values (EC50 450-600 ng/ml) and saturation of binding was achieved at low concentrations.\nChimAB 67A and 61D showed low (EC50 1000 ng/ml) and medium (EC50 2300 ng/ml) EC50 values, respectively (Fig. 12).\nRegarding binding to CLDN6 endogenously expressed in NEC8 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibited very low EC50 values (EC50 600-650 ng/ml) and saturation of binding was achieved at low concentrations, whereas chimAB 61D and 67A showed medium (EC50 1700 ng/ml) and high (EC50 6100 ng/ml) EC50 values, respectively (Fig. 13).\nRegarding binding to CLDN6 endogenously expressed in OV90 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibited very low EC50 values (EC50 550-600 ng/ml) and saturation of binding was achieved at low concentrations.\nChimAB 61D and 67A showed medium EC50 values (EC50 1500 ng/ml and EC50 2300 ng/ml, respectively) (Fig. 14)."
    },
    {
        "molecule_name": "chimAB 64A",
        "protein_target_name": "CLDN6",
        "binding_metric": "EC50",
        "value": "550-600",
        "unit": "ng/ml",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nRegarding binding to human CLDN6 stably expressed on the surface of HEK293 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibit very low EC50 values (EC50 450-600 ng/ml) and saturation of binding was achieved at low concentrations.\nChimAB 67A and 61D showed low (EC50 1000 ng/ml) and medium (EC50 2300 ng/ml) EC50 values, respectively (Fig. 12).\nRegarding binding to CLDN6 endogenously expressed in NEC8 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibited very low EC50 values (EC50 600-650 ng/ml) and saturation of binding was achieved at low concentrations, whereas chimAB 61D and 67A showed medium (EC50 1700 ng/ml) and high (EC50 6100 ng/ml) EC50 values, respectively (Fig. 13).\nRegarding binding to CLDN6 endogenously expressed in OV90 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibited very low EC50 values (EC50 550-600 ng/ml) and saturation of binding was achieved at low concentrations.\nChimAB 61D and 67A showed medium EC50 values (EC50 1500 ng/ml and EC50 2300 ng/ml, respectively) (Fig. 14)."
    },
    {
        "molecule_name": "chimAB 89A",
        "protein_target_name": "CLDN6",
        "binding_metric": "EC50",
        "value": "550-600",
        "unit": "ng/ml",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nRegarding binding to human CLDN6 stably expressed on the surface of HEK293 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibit very low EC50 values (EC50 450-600 ng/ml) and saturation of binding was achieved at low concentrations.\nChimAB 67A and 61D showed low (EC50 1000 ng/ml) and medium (EC50 2300 ng/ml) EC50 values, respectively (Fig. 12).\nRegarding binding to CLDN6 endogenously expressed in NEC8 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibited very low EC50 values (EC50 600-650 ng/ml) and saturation of binding was achieved at low concentrations, whereas chimAB 61D and 67A showed medium (EC50 1700 ng/ml) and high (EC50 6100 ng/ml) EC50 values, respectively (Fig. 13).\nRegarding binding to CLDN6 endogenously expressed in OV90 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibited very low EC50 values (EC50 550-600 ng/ml) and saturation of binding was achieved at low concentrations.\nChimAB 61D and 67A showed medium EC50 values (EC50 1500 ng/ml and EC50 2300 ng/ml, respectively) (Fig. 14)."
    },
    {
        "molecule_name": "chimAB 61D",
        "protein_target_name": "CLDN6",
        "binding_metric": "EC50",
        "value": "1500",
        "unit": "ng/ml",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nRegarding binding to human CLDN6 stably expressed on the surface of HEK293 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibit very low EC50 values (EC50 450-600 ng/ml) and saturation of binding was achieved at low concentrations.\nChimAB 67A and 61D showed low (EC50 1000 ng/ml) and medium (EC50 2300 ng/ml) EC50 values, respectively (Fig. 12).\nRegarding binding to CLDN6 endogenously expressed in NEC8 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibited very low EC50 values (EC50 600-650 ng/ml) and saturation of binding was achieved at low concentrations, whereas chimAB 61D and 67A showed medium (EC50 1700 ng/ml) and high (EC50 6100 ng/ml) EC50 values, respectively (Fig. 13).\nRegarding binding to CLDN6 endogenously expressed in OV90 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibited very low EC50 values (EC50 550-600 ng/ml) and saturation of binding was achieved at low concentrations.\nChimAB 61D and 67A showed medium EC50 values (EC50 1500 ng/ml and EC50 2300 ng/ml, respectively) (Fig. 14)."
    },
    {
        "molecule_name": "chimAB 67A",
        "protein_target_name": "CLDN6",
        "binding_metric": "EC50",
        "value": "2300",
        "unit": "ng/ml",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nRegarding binding to human CLDN6 stably expressed on the surface of HEK293 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibit very low EC50 values (EC50 450-600 ng/ml) and saturation of binding was achieved at low concentrations.\nChimAB 67A and 61D showed low (EC50 1000 ng/ml) and medium (EC50 2300 ng/ml) EC50 values, respectively (Fig. 12).\nRegarding binding to CLDN6 endogenously expressed in NEC8 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibited very low EC50 values (EC50 600-650 ng/ml) and saturation of binding was achieved at low concentrations, whereas chimAB 61D and 67A showed medium (EC50 1700 ng/ml) and high (EC50 6100 ng/ml) EC50 values, respectively (Fig. 13).\nRegarding binding to CLDN6 endogenously expressed in OV90 cells, anti-CLDN6 chimeric monoclonal antibodies chimAB 64A and 89A exhibited very low EC50 values (EC50 550-600 ng/ml) and saturation of binding was achieved at low concentrations.\nChimAB 61D and 67A showed medium EC50 values (EC50 1500 ng/ml and EC50 2300 ng/ml, respectively) (Fig. 14)."
    }
]